|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kossaï M, Leary A, Scoazec JY and Genestie
C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49.
2018. View Article : Google Scholar
|
|
4
|
Angioli R, Palaia I, Zullo MA, Muzii L,
Manci N, Calcagno M and Panici PB: Diagnostic open laparoscopy in
the management of advanced ovarian cancer. Gynecol Oncol.
100:455–461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ray-Coquard I, Mirza MR, Pignata S,
Walther A, Romero I and du Bois A: Therapeutic options following
second-line platinum-based chemotherapy in patients with recurrent
ovarian cancer: Comparison of active surveillance and maintenance
treatment. Cancer Treat Rev. 90:1021072020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuroki L and Guntupalli SR: Treatment of
epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deb B, Uddin A and Chakraborty S: miRNAs
and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mihanfar A, Fattahi A and Nejabati HR:
MicroRNA-mediated drug resistance in ovarian cancer. J Cell
Physiol. 234:3180–3191. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dinh P, Harnett P, Piccart-Gebhart MJ and
Awada A: New therapies for ovarian cancer: Cytotoxics and
molecularly targeted agents. Crit Rev Oncol Hematol. 67:103–112.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smolle E, Taucher V, Pichler M, Petru E,
Lax S and Haybaeck J: Targeting signaling pathways in epithelial
ovarian cancer. Int J Mol Sci. 14:9536–9555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu L, Wu H, Jiang C, Wang H, Gao B, Yan S,
Qi Y and Zhou S: Dacomitinib, a new pan-EGFR inhibitor, is
effective in killing ovarian cancer cells. Discov Med. 22:297–309.
2016.PubMed/NCBI
|
|
12
|
Camblin AJ, Tan G, Curley MD, Yannatos I,
Iadevaia S, Rimkunas V, Mino-Kenudson M, Bloom T, Schoeberl B,
Drummond DC, et al: Dual targeting of IGF-1R and ErbB3 as a
potential therapeutic regimen for ovarian cancer. Sci Rep.
9:168322019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pradeep S, Kim SW, Wu SY, Nishimura M,
Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ,
Bischoff FZ, et al: Hematogenous metastasis of ovarian cancer:
Rethinking mode of spread. Cancer Cell. 26:77–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li LW, Xiao HQ, Ma R, Yang M, Li W and Lou
G: miR-152 is involved in the proliferation and metastasis of
ovarian cancer through repression of ERBB3. Int J Mol Med.
41:1529–1535. 2018.PubMed/NCBI
|
|
15
|
Gordon AN, Finkler N, Edwards RP, Garcia
AA, Crozier M, Irwin DH and Barrett E: Efficacy and safety of
erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor, in patients with advanced ovarian
carcinoma: Results from a phase II multicenter study. Int J Gynecol
Cancer. 15:785–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schilder RJ, Sill MW, Chen X, Darcy KM,
Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H and Godwin AK:
Phase II study of gefitinib in patients with relapsed or persistent
ovarian or primary peritoneal carcinoma and evaluation of epidermal
growth factor receptor mutations and immunohistochemical
expression: A gynecologic oncology group study. Clin Cancer Res.
11:5539–5548. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao BC, Lin CC and Yang JC: Second and
third-generation epidermal growth factor receptor tyrosine kinase
inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol.
27:94–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Momeny M, Zarrinrad G, Moghaddaskho F,
Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili
F, Eyvani H, Barghi F, et al: Dacomitinib, a pan-inhibitor of ErbB
receptors, suppresses growth and invasive capacity of
chemoresistant ovarian carcinoma cells. Sci Rep. 7:42042017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu J, Zhang L, Li H, Wu S and Liu Z: Nrf2
induced cisplatin resistance in ovarian cancer by promoting CD99
expression. Biochem Biophys Res Commun. 518:698–705. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li R, Ong SL, Tran LM, Jing Z, Liu B, Park
SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, et al: Chronic
IL-1beta-induced inflammation regulates epithelial-to-mesenchymal
transition memory phenotypes via epigenetic modifications in
non-small cell lung cancer. Sci Rep. 10:3772020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miao Y, Liu G and Liu L: Histone
methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression
and promotes epithelial mesenchymal transition of osteosarcoma.
Cancer Cell Int. 21:22021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao L, Fan T, Shi Z, Ding C, Zhang C,
Yuan Z, Sun Q, Tan C, Chu B and Jiang Y: Design, synthesis and
evaluation of novel ErbB/HDAC multitargeted inhibitors with
selectivity in EGFRT790M mutant cell lines. Eur J Med
Chem. 213:1131732021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hyokai S, Tanaka H, Aihara N and Kamiie J:
Expression of P-glycoprotein and breast cancer resistance protein
in three cases of canine lymphoma showing drug resistance. J Vet
Med Sci. Jan 29–2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sims AH, Zweemer AJ, Nagumo Y, Faratian D,
Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ and Langdon
SP: Defining the molecular response to trastuzumab, pertuzumab and
combination therapy in ovarian cancer. Br J Cancer. 106:1779–1789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toolabi M, Moghimi S, Bakhshaiesh TO,
Salarinejad S, Aghcheli A, Hasanvand Z, Nazeri E, Khalaj A,
Esmaeili R and Foroumadi A:
6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic
agents: Design, synthesis and structure-activity relationship
studies. Eur J Med Chem. 185:1117862020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH,
Hao ZJ, Tian B, He HW and Guo XL: Pantoprazole pretreatment
elevates sensitivity to vincristine in drug-resistant oral
epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother.
120:1094782019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hao Sun and Wu YL: Dacomitinib in
non-small-cell lung cancer: A comprehensive review for clinical
application. Future Oncol. 15:2769–2777. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hurvitz SA, Caswell-Jin JL, McNamara KL,
Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L,
Allen H, et al: Pathologic and molecular responses to neoadjuvant
trastuzumab and/or lapatinib from a phase II randomized trial in
HER2-positive breast cancer (TRIO-US B07). Nat Commun. 11:58242020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamashita T, Masuda N, Saji S, Araki K,
Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, et
al: Trastuzumab, pertuzumab, and eribulin mesylate versus
trastuzumab, pertuzumab, and a taxane as a first-line or
second-line treatment for HER2-positive, locally advanced or
metastatic breast cancer: Study protocol for a randomized
controlled, non-inferiority, phase III trial in Japan
(JBCRG-M06/EMERALD). Trials. 21:3912020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang X and Tang J: Human la protein: An
RNA-binding protein involved in ovarian cancer development and
multidrug resistance. Onco Targets Ther. 13:10721–10727. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Passaro A, Mok T, Peters S, Popat S, Ahn
MJ and de Marinis F: Recent advances on the role of EGFR tyrosine
kinase inhibitors in the management of NSCLC with uncommon, non
exon 20 insertions, EGFR mutations. J Thorac Oncol.
S1556-0864:31102–31103. 2020.(Epub ahead of print).
|
|
33
|
Engelman JA, Zejnullahu K, Gale CM,
Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov
GN, Bradner JE, et al: PF00299804, an irreversible pan-ERBB
inhibitor, is effective in lung cancer models with EGFR and ERBB2
mutations that are resistant to gefitinib. Cancer Res.
67:11924–11932. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gonzales AJ, Hook KE, Althaus IW, Ellis
PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson
JM, et al: Antitumor activity and pharmacokinetic properties of
PF-00299804, a second-generation irreversible pan-erbB receptor
tyrosine kinase inhibitor. Mol Cancer Ther. 7:1880–1889. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi
H, Masuda J, Ozawa H and Ogiwara Y: Targeting oncoimmune drivers of
cancer metastasis. Cancers (Basel). 13:5542021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Klymenko Y, Kim O and Stack MS: Complex
determinants of epithelial: Mesenchymal phenotypic plasticity in
ovarian cancer. Cancers (Basel). 9:1042017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahmed AR and Muhammad EM: E-cadherin and
CD10 expression in atypical hyperplastic and malignant endometrial
lesions. J Egypt Natl Canc Inst. 26:211–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goldstein LJ, Galski H, Fojo A, Willingham
M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al:
Expression of a multidrug resistance gene in human cancers. J Natl
Cancer Inst. 81:116–124. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Muthiah D, Henshaw GK, DeBono AJ, Capuano
B, Scammells PJ and Callaghan R: Overcoming P-glycoprotein-mediated
drug resistance with noscapine derivatives. Drug Metab Dispos.
47:164–172. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Q, Liu X, Luo Z, Wang S, Lin J, Xie
Z, Li M, Li C, Cao H, Huang Q, et al: Chloride channel-3 mediates
multidrug resistance of cancer by upregulating P-glycoprotein
expression. J Cell Physiol. 234:6611–6623. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu L, Cai J, Yang Q, Ding H, Wu L, Li T
and Wang Z: Prognostic significance of several biomarkers in
epithelial ovarian cancer: A meta-analysis of published studies. J
Cancer Res Clin Oncol. 139:1257–1277. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Poursheikhani A, Yousefi H,
Tavakoli-Bazzaz J and Seyed HG: EGFR blockade reverses cisplatin
resistance in human epithelial ovarian cancer cells. Iran Biomed J.
24:370–378. 2020.PubMed/NCBI
|
|
44
|
Perrotta C, Cervia D, Di Renzo I, Moscheni
C, Bassi MT, Campana L, Martelli C, Catalani E, Giovarelli M,
Zecchini S, et al: Nitric oxide generated by tumor-associated
macrophages is responsible for cancer resistance to cisplatin and
correlated with syntaxin 4 and acid sphingomyelinase inhibition.
Front Immunol. 9:11862018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu H, Zhang Z, Li P, Lu X, Chen B and Lan
T: Expression of PKG2 in ovarian cancer and its effect on epidermal
growth factor receptor. J BUON. 25:729–735. 2020.PubMed/NCBI
|
|
46
|
Pang J, Jiang P, Wang Y, Jiang L, Qian H,
Tao Y, Shi R, Gao J, Chen Y and Wu Y: Cross-linked hyaluronan gel
inhibits the growth and metastasis of ovarian carcinoma. J Ovarian
Res. 11:222018. View Article : Google Scholar : PubMed/NCBI
|
